30 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Article Searches
Teva stock trades in the green for seventh straight session https://seekingalpha.com/news/4084589-teva-on-track-for-seventh-straight-day-of-gains?source=feed_tag_israel Mar 27, 2024 - Teva Pharmaceutical (TEVA) shares are on the rise, gaining for the 7th consecutive day.
Teva Pharmaceutical Industries: Potential Outweighs Concerns https://seekingalpha.com/article/4680308-teva-pharmaceutical-industries-potential-outweighs-concerns?source=feed_tag_israel Mar 25, 2024 - Teva Pharmaceutical is deeply undervalued, trading at a 77% discount per my calculations. The new CEO's turnaround plan looks promising. Find out why TEVA stock is a Buy.
Will Corcept (CORT) Bank on Korlym in 2024 Amid Stiff Rivalry? https://www.zacks.com/stock/news/2245567/will-corcept-cort-bank-on-korlym-in-2024-amid-stiff-rivalry?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2245567 Mar 25, 2024 - Corcept (CORT) expects its sole marketed drug, Korlym, approved for treating Cushing's syndrome, to generate incremental sales and combat stiff competition.
GSK Follows Rivals, to Cap Out-of-Pocket Inhaler Cost in US https://www.zacks.com/stock/news/2244405/gsk-follows-rivals-to-cap-out-of-pocket-inhaler-cost-in-us?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2244405 Mar 21, 2024 - GSK plc (GSK) plans to lower the prices of its entire inhaled respiratory products to $35 per month in the United States. The company intends to start this in 2025.
AstraZeneca (AZN) Follows Boehringer, to Cap Inhaler Cost in US https://www.zacks.com/stock/news/2243035/astrazeneca-azn-follows-boehringer-to-cap-inhaler-cost-in-us?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2243035 Mar 19, 2024 - AstraZeneca (AZN) plans to lower the prices of its inhaled respiratory products to $35 per month in the United States. However, the company intends to start this in June 2024.
Teva upgraded at J.P. Morgan on upcoming catalysts https://seekingalpha.com/news/4077679-teva-stock-upgraded-jp-morgan-catalysts?source=feed_tag_israel Mar 08, 2024 - Teva Pharmaceutical (TEVA) receives an upgrade from J.P. Morgan, on upcoming positive catalysts as the bank reviews its specialty pharma coverage. Read more here.
Teva And Alvotech: Simlandi Approval Opens New Generic Market Opportunities https://seekingalpha.com/article/4673481-teva-alvotech-simlandi-approval-opens-new-generic-market-opportunities?source=feed_tag_israel Feb 26, 2024 - Teva's stock has risen 32% since December, outperforming the SPY, buoyed by FDA approval of Simlandi, a biosimilar to Humira. Learn more about TEVA stock here.
Teva and Jiangsu announce partnership for distribution of AUSTEDO in China https://seekingalpha.com/news/4071489-teva-and-jiangsu-announce-partnership-for-distribution-of-austedo-in-china?source=feed_tag_israel Feb 26, 2024 - Teva Pharmaceutical and Jiangsu Nhwa forge a strategic partnership to enhance patient access to AUSTEDO, a drug for neurodegenerative and movement...
Teva Pharmaceutical: I Need To See Top-Line Growth Return Before Starting A Position https://seekingalpha.com/article/4670634-teva-pharmaceutical-i-need-to-see-growth-before-starting-a-position?source=feed_tag_israel Feb 15, 2024 - Teva Pharmaceutical's weak financial performance, declining revenues, and industry uncertainties make it a risky investment. Read why I rate TEVA stock a hold.
Teva upgraded to Overweight at Piper Sandler on multiple expansion https://seekingalpha.com/news/4065532-teva-stock-upgraded-piper-sandler-valuation?source=feed_tag_israel Feb 12, 2024 - Piper Sandler upgraded Teva Pharmaceutical (TEVA) to Overweight and raised its price target to $19 from $12 per share citing valuation. Read more here.

Pages: 123

Page 1>